RNA splicing factors as oncoproteins and tumour suppressors Review uri icon


MeSH Major

  • Genes, Tumor Suppressor
  • Oncogene Proteins
  • RNA Splicing Factors


  • The recent genomic characterization of cancers has revealed recurrent somatic point mutations and copy number changes affecting genes encoding RNA splicing factors. Initial studies of these 'spliceosomal mutations' suggest that the proteins bearing these mutations exhibit altered splice site and/or exon recognition preferences relative to their wild-type counterparts, resulting in cancer-specific mis-splicing. Such changes in the splicing machinery may create novel vulnerabilities in cancer cells that can be therapeutically exploited using compounds that can influence the splicing process. Further studies to dissect the biochemical, genomic and biological effects of spliceosomal mutations are crucial for the development of cancer therapies targeted at these mutations.

publication date

  • June 24, 2016



  • Review



  • eng

PubMed Central ID

  • PMC5094465

Digital Object Identifier (DOI)

  • 10.1038/nrc.2016.51

PubMed ID

  • 27282250

Additional Document Info

start page

  • 413

end page

  • 30


  • 16


  • 7